|
8 February 2010
Silence Therapeutics Receives Notice of Allowance for RNAi Patent Covering Novel Cancer Target
|
|
Read more...
|
|
5 February 2010
Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference |
|
Read more...
|
|
5 January 2010
Silence and Intradigm complete merger to form a leading company in the field of RNAi |
|
Read more...
|
|
4 January 2010
Shareholders pass all resolutions at EGM |
|
Read more...
|
|
16 December 2009
Silence Therapeutics to merge with Intradigm Corp to create leading RNAi therapeutics company |
|
Read more...
|
|
16 December 2009
Admission Document – Circular to Shareholders in full
download Admission Document |
|
14 December 2009
Shareholders pass all resolutions at AGM |
|
Read more...
|
|
15 October 2009
Silence Therapeutics’ core patent upheld |
|
Read more...
|
|
30 September 2009
Silence announces Interim Results for the six months ended 30 June 2009 |
|
Read more...
|
|
29 September 2009
Silence announces temporary suspension of shares pending outcome of M&A talks |
|
Read more...
|
|
17 September 2009
Silence will release its interim results for the 6 months to 30 June 2009 on 30 September 2009 |
|
Read more...
|
|
27 August 2009
Silence Therapeutics signs siRNA delivery collaboration with Dainippon Sumitomo Pharma |
|
Read more...
|
|
23 June 2009
Silence announces dosing of first patient in Atu027 cancer trial |
|
Read more...
|
|
3 June 2009
Silence receives approval to commence Phase I clinical trial with Atu027 |
|
Read more...
|
|
21 January 2009
Successful oppostion to 2nd EP on Keutzer-Limmer |
|
Read more...
|
|
9 January 2009
EPO grants Silence Therapeutics’ Patent |
|
Read more...
|
